Prediction of Lymphatic Metastasis in Esophageal Cancer by CT Radiomics
NCT ID: NCT03237130
Last Updated: 2021-02-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
133 participants
OBSERVATIONAL
2017-02-15
2020-05-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Predictive Value of CT-PET in Esophageal Cancer
NCT02385604
The Role of PET/MRI in Predicting the Outcome of Definitive Chemoradiotherapy for Esophageal Cancer Patients
NCT05855278
PET in Guiding Cervical Lymphadenectomy (ECTOP-2003)
NCT03244566
Quantitative Evaluation of Metastatic Lymph Nodes With Dynamic 18F-FDG PET/CT in Patients With ESCC
NCT04514822
PET-CT Based Radiotherapy in Esophageal Cancer Patients
NCT01156831
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
preoperative enhanced chest CT
The cohort contains patients with preoperative therapies and patients without preoperative therapies. Each patient receives regular preoperative enhanced chest CT; for patients with preoperative therapies, they usually undergo twice enhanced chest CT examination at before and after preoperative therapies, the CT images after preoperative therapies will be used for analysis
preoperative enhanced chest CT examination
Each patient will receive preoperative enhanced chest CT examination, and their CT images will be used for analysis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
preoperative enhanced chest CT examination
Each patient will receive preoperative enhanced chest CT examination, and their CT images will be used for analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* scheduled to preoperative enhanced chest CT and undergo surgery
* sign the patient informed consent
Exclusion Criteria
* inavailable pathological results for local lymph node status
* inquality of CT images for feature extraction
* patient quit
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University Cancer Hospital & Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sun Ying-Shi
Chairman of Dept.Radiology of Beijing Cancer Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ying-Shi Sun, MD
Role: STUDY_CHAIR
Dept.Radiology,Peking University Cancer Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTRadiomics-LMesophagus-BNSF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.